NCT01362400 2014-05-19A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerInfinity Pharmaceuticals, Inc.Phase 2 Completed226 enrolled
NCT00431015 2012-12-10Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)Infinity Pharmaceuticals, Inc.Phase 1/2 Completed88 enrolled